ONCO vs. CARA, COCP, TENX, XCUR, ATHA, GOVX, MIRA, BTAI, CYTH, and APRE
Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Cara Therapeutics (CARA), Cocrystal Pharma (COCP), Tenax Therapeutics (TENX), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry.
Onconetix vs.
Onconetix (NASDAQ:ONCO) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
Onconetix has higher earnings, but lower revenue than Cara Therapeutics.
Cara Therapeutics received 667 more outperform votes than Onconetix when rated by MarketBeat users.
Onconetix has a beta of 3.18, meaning that its stock price is 218% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Cara Therapeutics has a consensus price target of $27.84, suggesting a potential upside of 505.22%. Given Cara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than Onconetix.
Cara Therapeutics has a net margin of -1,099.76% compared to Onconetix's net margin of -2,758.89%. Onconetix's return on equity of 0.00% beat Cara Therapeutics' return on equity.
In the previous week, Cara Therapeutics had 1 more articles in the media than Onconetix. MarketBeat recorded 1 mentions for Cara Therapeutics and 0 mentions for Onconetix. Onconetix's average media sentiment score of 0.00 equaled Cara Therapeutics'average media sentiment score.
23.9% of Onconetix shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 11.4% of Onconetix shares are held by insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Cara Therapeutics beats Onconetix on 7 of the 13 factors compared between the two stocks.
Get Onconetix News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Onconetix Competitors List
Related Companies and Tools
This page (NASDAQ:ONCO) was last updated on 1/22/2025 by MarketBeat.com Staff
